Tesamorelin
Egrifta / Egrifta WR
Tesamorelin (Egrifta) is an FDA-approved GHRH analog indicated for HIV-associated lipodystrophy. It stimulates endogenous GH release and has Phase 3 trial data supporting its approved use.
Overview
Tesamorelin is a synthetic 44-amino acid peptide analog of human growth hormone-releasing hormone (GHRH), developed by Theratechnologies. It preserves the full native GHRH sequence with an added N-terminal trans-3-hexenoic acid modification that improves stability against enzymatic degradation, extending its functional half-life compared to shorter analogs like sermorelin.
Tesamorelin is the only GHRH analog currently carrying active FDA approval in the United States. It is approved under the brand name Egrifta (and the newer Egrifta WR formulation) for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy — a condition characterized by abnormal fat distribution associated with antiretroviral therapy. An updated F8 formulation received FDA approval in early 2025, simplifying the dosing regimen.
Research context
Tesamorelin's FDA approval is supported by robust Phase 3 clinical trial data. Pivotal trials enrolled over 800 HIV-infected patients with lipodystrophy and demonstrated significant reductions in visceral adipose tissue after 26 weeks of daily subcutaneous administration, with extension studies showing sustained effects at 52 weeks. Additional research has shown associated improvements in lipid profiles, including triglyceride and cholesterol ratios.
Off-label interest in tesamorelin has grown in areas including body composition in non-HIV populations, non-alcoholic fatty liver disease (NAFLD/MASH), and age-related growth hormone decline. However, controlled clinical trial evidence for these off-label uses is limited compared to the HIV-lipodystrophy data. Tesamorelin stimulates endogenous GH release through the pituitary, meaning it preserves the body's natural feedback mechanisms rather than supplying exogenous GH directly.
Safety and regulatory framing
FDA-approved (Egrifta / Egrifta WR) for HIV-associated lipodystrophy
Tesamorelin (Egrifta/Egrifta WR) is FDA-approved for a specific indication: reduction of excess abdominal fat in adults with HIV and lipodystrophy. It is a prescription medication administered daily by subcutaneous injection. Common adverse reactions include joint pain, injection site reactions, pain in extremities, peripheral edema, and muscle pain.
Off-label use of tesamorelin in non-HIV populations has not been evaluated in Phase 3 trials and lacks the same level of regulatory-grade evidence. Tesamorelin is not indicated for general weight loss or anti-aging purposes. Regulations vary by country. Readers should consult a licensed healthcare provider for decisions about any medication.
References
- Falutz J, et al. "Reduction of Trunk Fat with Tesamorelin in HIV." NEJM (2010) ↗New England Journal of Medicine
- Egrifta (Tesamorelin) Prescribing Information — FDA Label ↗FDA.gov
- Stanley TL, et al. "Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease." JAMA (2014) ↗JAMA
- FDA Approves F8 Formulation of Tesamorelin (2025) ↗Contagion Live
Research information only
Peptide Daily is an informational resource only. Peptide research chemicals are not approved for human use by the FDA unless otherwise noted. Nothing on this site constitutes medical advice. Consult a qualified healthcare provider before using any peptide or research chemical.
New regulatory shifts matter as much as the peptide itself
Subscribe for editorial updates when major price moves, lab tests, or regulatory events affect the compounds you're tracking.
Weekly update
Get weekly peptide price intel
No spam, unsubscribe anytime.
Keep exploring the research context
Sermorelin
Sermorelin (GHRH 1-29) was previously FDA-approved for pediatric GH deficiency and is now available through compounding. It stimulates pituitary GH release and has a longer clinical history than most research peptides.
CJC-1295
CJC-1295 is a GHRH analog that stimulates pituitary GH release. Limited human clinical data exists; it is not FDA-approved and is classified as a compounding safety concern.
Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that triggers pulsatile GH release without significant cortisol or prolactin elevation. Not FDA-approved; WADA-prohibited.